Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease
Summary
- Switching ART to a more lipid-friendly regimen may be a reasonable approach in patients who are unable to achieve desired lipid goals through other means
This strategy is best undertaken in patients on an initial regimen, where lipid derangement is considered largely due to ART
Switching NRTIs - Clinical trials have demonstrated improvement of dyslipidemia in patients who switched from abacavir/lamivudine to emtricitabine/tenofovir DF in combination with either efavirenz or a boosted PI[Moyle 2015; Behrens 2012; Campo 2013]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content